Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ENOB

Enochian Biosciences (ENOB) Stock Price, News & Analysis

Enochian Biosciences logo

About Enochian Biosciences Stock (NASDAQ:ENOB)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.40
$0.79
52-Week Range
N/A
Volume
88,300 shs
Average Volume
137,347 shs
Market Capitalization
$40.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Remove Ads
Receive ENOB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENOB Stock News Headlines

Thinking of buying Nvidia? Read this first
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Eastern & Oriental Bhd (ENOB)
See More Headlines

ENOB Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Enochian Biosciences investors own include Carnival Co. & (CCL), Ashford Hospitality Trust (AHT), Assertio (ASRT), Peabody Energy (BTU), PlayAGS (AGS), Alliance Resource Partners (ARLP) and Astronics (ATRO).

Company Calendar

Today
4/05/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ENOB
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
N/A

Miscellaneous

Free Float
45,625,000
Market Cap
$40.80 million
Optionable
Not Optionable
Beta
1.09
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:ENOB) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners